Drugs / YPEG-rhG-CSF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02005458 | Dec 2013 → Mar 2017 | breast cancer, non-small cell lung carcinoma | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YPEG-rhG-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02005458 ↗ |
| Route | Subcutaneous | “20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle” NCT02005458 ↗ |